Citation

Han JJ, Faletsky A, Barbieri JS, Mostaghimi A. Dermatol. Ther. (Heidelb) 2021; 11(1): 79-91.

Copyright

(Copyright © 2021, Holtzbrinck Springer Nature Publishing Group)

DOI

10.1007/s13555-020-00481-w

PMID

unavailable

Abstract

Acne vulgaris is a chronic inflammatory skin disease with a multifactorial pathogenesis. Although a variety of acne treatments are available, limitations of current therapies include tolerability, antimicrobial resistance, and costs and patient burden associated with monitoring. This narrative review focuses on emerging treatments and updates on the management of acne. Clascoterone, sarecycline, trifarotene, and novel lotion formulations of tretinoin and tazarotene have been evaluated in clinical trials and provide new options for treatment. Emerging data on the safety and efficacy of spironolactone and isotretinoin challenge current conventions and suggest a need to reconsider drug monitoring guidelines and risk prevention systems. Additional head-to-head data are needed to confirm these novel treatments' utility in treating acne. © 2021, The Author(s).

Language: en

Keywords

human; suicide; systematic review; Review; depression; drug use; acne; isotretinoin; pain; pregnancy; sex; race; vomiting; treatment planning; priority journal; headache; anxiety disorder; practice guideline; drug mechanism; drug efficacy; nausea; Acne; erythema; alopecia; skin irritation; antibiotic agent; risk reduction; mental instability; drug monitoring; drug formulation; drug indication; spironolactone; retinoic acid; Isotretinoin; dry skin; retinoid; Retinoids; skin burning sensation; vagina candidiasis; tazarotene; skin defect; clinical evaluation; rhinopharyngitis; skin exfoliation; sunburn; vagina mycosis; Spironolactone; oropharynx pain; clascoterone; Clascoterone; lotion; sarecycline; Sarecycline; trifarotene